Can a new drug shrink Hard-to-Treat gynecological tumors?
NCT ID NCT07769229
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This phase II trial is testing an investigational drug called BL-M09D1 in people with advanced gynecological cancers (such as ovarian, cervical, or endometrial cancer) and other solid tumors that have progressed despite standard treatment. The drug is given by intravenous infusion every three weeks. The study aims to see if the drug can shrink tumors and to evaluate its safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BL-M09D1, an investigational drug given by intravenous infusion
- What this could lead to
- If successful, this could lead to a new treatment option for people with advanced gynecological cancers and other solid tumors that have not responded to standard therapies.
- What could go wrong
- This is an early-phase trial, so the drug may not work as hoped or may cause significant side effects. The results will need confirmation in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fujian Cancer Hospital
Fuzhou, Fujian, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection shrink Hard-to-Treat tumors?
- Can Long-Term tucatinib use remain safe for HER2-Positive cancers?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can an antiviral make radiation more effective against cervical cancer?